Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.

Ford N, Lee J, Andrieux-Meyer I, Calmy A.

HIV AIDS (Auckl). 2011;3:35-44. doi: 10.2147/HIV.S14559. Epub 2011 Apr 28.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.

Garvey L, Winston A.

Expert Opin Investig Drugs. 2009 Jul;18(7):1035-41. doi: 10.1517/13543780903055056. Review.

PMID:
19548857
4.

Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.

James C, Preininger L, Sweet M.

Am J Health Syst Pharm. 2012 May 15;69(10):857-61. doi: 10.2146/ajhp110395.

PMID:
22555080
5.

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients.

Putcharoen O, Kerr SJ, Ruxrungtham K.

HIV AIDS (Auckl). 2013 Sep 16;5:231-41. doi: 10.2147/HIV.S25712. Review.

6.

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

Lee JS, Calmy A, Andrieux-Meyer I, Ford N.

HIV AIDS (Auckl). 2012;4:5-15. doi: 10.2147/HIV.S20993. Epub 2012 Jan 12.

8.
9.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
10.

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.

Maartens G, Decloedt E, Cohen K.

Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Review.

PMID:
20032533
11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
13.

Rilpivirine: a new addition to the anti-HIV-1 armamentarium.

Miller CD, Crain J, Tran B, Patel N.

Drugs Today (Barc). 2011 Jan;47(1):5-15. doi: 10.1358/dot.2011.47.1.1583188. Review.

PMID:
21373646
14.

Improving first-line antiretroviral therapy in resource-limited settings.

Ford N, Calmy A.

Curr Opin HIV AIDS. 2010 Jan;5(1):38-47. doi: 10.1097/COH.0b013e3283339b41. Review.

PMID:
20046146
15.

Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.

Li SL, Xu P, Zhang L, Sun GX, Lu ZJ.

HIV Clin Trials. 2015 Jan-Feb;16(1):22-9. doi: 10.1179/1528433614Z.0000000007. Epub 2015 Jan 27.

PMID:
25777186
16.
17.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
18.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.

Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, Hartwell D, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(20):1-174, iii-iv. Review.

19.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
20.

Long-acting injectable antiretrovirals for HIV treatment and prevention.

Spreen WR, Margolis DA, Pottage JC Jr.

Curr Opin HIV AIDS. 2013 Nov;8(6):565-71. doi: 10.1097/COH.0000000000000002. Review.

Items per page

Supplemental Content

Write to the Help Desk